BrainsWay Ltd. (BWAY)
NASDAQ: BWAY · Real-Time Price · USD
9.24
+0.28 (3.13%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally.

It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases.

The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd.
BrainsWay logo
Country Israel
Founded 2003
IPO Date Apr 17, 2019
Industry Medical Devices
Sector Healthcare
Employees 134
CEO Hadar Levy

Contact Details

Address:
Bynet Building, 3rd Floor
Jerusalem, 9777518
Israel
Phone 972 2 582 4030
Website brainsway.com

Stock Details

Ticker Symbol BWAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001076643
CUSIP Number 10501L106
ISIN Number US10501L1061
Employer ID 04-3285165
SIC Code 7389

Key Executives

Name Position
Hadar Levy Chief Executive Officer
Avner Hagai Founder and Director
Prof. Abraham Zangen Co-Founder, Member of Scientific Advisory Board and Director
Dr. Yiftach Roth Ph.D. Founder and Chief Scientific Officer
Ido Marom Chief Financial Officer
Gilead Moiseyev Chief Technology Officer
Menachem C. Klein Esq. Vice President, General Counsel and Corporate Secretary
Ross Mitchell Vice President of Global Marketing
Hillegonda Groen Vice President of International Sales
Dr. Richard A. Bermudes M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 10, 2010 REVOKED Filing
Sep 10, 2001 4 Statement of changes in beneficial ownership of securities
Sep 5, 2001 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 5, 2001 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 5, 2001 8-K Current Report
Aug 15, 2001 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 8, 2001 4 Statement of changes in beneficial ownership of securities
Aug 8, 2001 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jul 5, 2001 10-K Annual Report
Jun 27, 2001 8-K Current Report